Aidigong Maternal & Child Health 将来の成長

Future 基準チェック /06

現在、 Aidigong Maternal & Child Healthの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Healthcare 収益成長	18.5%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

Recent updates

Aidigong Maternal & Child Health Limited's (HKG:286) 44% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Nov 09

Pinning Down Aidigong Maternal & Child Health Limited's (HKG:286) P/S Is Difficult Right Now

Sep 25

Investors Don't See Light At End Of Aidigong Maternal & Child Health Limited's (HKG:286) Tunnel And Push Stock Down 26%

Jun 06

Take Care Before Jumping Onto Aidigong Maternal & Child Health Limited (HKG:286) Even Though It's 28% Cheaper

Mar 22

A Look At The Fair Value Of Aidigong Maternal & Child Health Limited (HKG:286)

Jul 06

Aidigong Maternal & Child Health Limited (HKG:286) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough

Jun 14

Calculating The Intrinsic Value Of Aidigong Maternal & Child Health Limited (HKG:286)

Mar 27

Is Aidigong Maternal & Child Health Limited (HKG:286) Trading At A 24% Discount?

Dec 21

Is Aidigong Maternal & Child Health (HKG:286) Using Debt In A Risky Way?

Oct 13

Estimating The Fair Value Of Aidigong Maternal & Child Health Limited (HKG:286)

Sep 02

Aidigong Maternal & Child Health (HKG:286) Has A Somewhat Strained Balance Sheet

Jun 29

Aidigong Maternal & Child Health (HKG:286) Use Of Debt Could Be Considered Risky

Aug 31

Do Institutions Own Aidigong Maternal & Child Health Limited (HKG:286) Shares?

Feb 21

Is Aidigong Maternal & Child Health Limited's (HKG:286) Stock Price Struggling As A Result Of Its Mixed Financials?

Jan 17

Aidigong Maternal & Child Health's(HKG:286) Share Price Is Down 14% Over The Past Three Years.

Dec 12

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Aidigong Maternal & Child Health は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

SEHK:286 - アナリストの将来予測と過去の財務データ ( )HKD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2024	522	-193	34	70	N/A
3/31/2024	538	-185	40	77	N/A
12/31/2023	555	-177	46	83	N/A
9/30/2023	606	-152	131	168	N/A
6/30/2023	658	-127	216	254	N/A
3/31/2023	669	-146	147	184	N/A
12/31/2022	680	-165	77	115	N/A
9/30/2022	664	-123	72	103	N/A
6/30/2022	647	-80	66	91	N/A
3/31/2022	645	-37	73	98	N/A
12/31/2021	643	5	80	105	N/A
9/30/2021	622	-189	66	84	N/A
6/30/2021	601	-384	51	63	N/A
3/31/2021	601	-383	4	16	N/A
12/31/2020	601	-381	-43	-32	N/A
9/30/2020	653	-172	-119	-105	N/A
6/30/2020	704	37	-195	-178	N/A
3/31/2020	657	24	-106	-89	N/A
12/31/2019	611	11	-17	0	N/A
9/30/2019	492	3	5	27	N/A
6/30/2019	374	-5	28	53	N/A
3/31/2019	376	-1	21	47	N/A
12/31/2018	377	2	15	41	N/A
9/30/2018	452	2	-41	-17	N/A
6/30/2018	528	3	-96	-75	N/A
3/31/2018	501	2	N/A	-62	N/A
12/31/2017	475	1	N/A	-50	N/A
9/30/2017	496	8	N/A	-90	N/A
6/30/2017	517	14	N/A	-131	N/A
3/31/2017	536	28	N/A	-128	N/A
12/31/2016	555	42	N/A	-124	N/A
9/30/2016	583	51	N/A	-4	N/A
6/30/2016	610	59	N/A	116	N/A
3/31/2016	570	47	N/A	116	N/A
12/31/2015	530	34	N/A	117	N/A
6/30/2015	485	27	N/A	-56	N/A
3/31/2015	422	24	N/A	-72	N/A
12/31/2014	360	20	N/A	-89	N/A
6/30/2014	17	-10	N/A	-21	N/A
3/31/2014	13	-6	N/A	-50	N/A
12/31/2013	9	-3	N/A	-79	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 286の予測収益成長が貯蓄率 ( 2.3% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: 286の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: 286の収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: 286の収益がHong Kong市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: 286の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 286の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Aidigong Maternal & Child Health 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Aidigong Maternal & Child Health Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023

Price target decreased to HK$0.60

Aidigong Maternal & Child Health Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Price target decreased to HK$0.65

Recent updates

New major risk - Shareholder dilution

Aidigong Maternal & Child Health Limited's (HKG:286) 44% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Now 33% undervalued

Now 26% undervalued

First half 2024 earnings released: HK$0.33 loss per share (vs HK$0.22 loss in 1H 2023)

New minor risk - Share price stability

Pinning Down Aidigong Maternal & Child Health Limited's (HKG:286) P/S Is Difficult Right Now

Aidigong Maternal & Child Health Limited(SEHK:286) dropped from S&P Global BMI Index

First half 2024 earnings released: HK$0.33 loss per share (vs HK$0.22 loss in 1H 2023)

Aidigong Maternal & Child Health Limited to Report First Half, 2024 Results on Aug 30, 2024

Aidigong Maternal & Child Health Limited, Annual General Meeting, Jun 28, 2024

Investors Don't See Light At End Of Aidigong Maternal & Child Health Limited's (HKG:286) Tunnel And Push Stock Down 26%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Take Care Before Jumping Onto Aidigong Maternal & Child Health Limited (HKG:286) Even Though It's 28% Cheaper

Aidigong Maternal & Child Health Limited has filed a Follow-on Equity Offering in the amount of HKD 62.09021 million.

Aidigong Maternal & Child Health Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

New minor risk - Insider selling

Chairman & CEO recently sold HK$8.4m worth of stock

New major risk - Share price stability

Chairman & CEO recently bought HK$1.4m worth of stock

New minor risk - Shareholder dilution

Chairman of the Board & CEO recently bought HK$247k worth of stock

Aidigong Maternal & Child Health Limited Announces Board and Committee Changes

Aidigong Maternal & Child Health Limited Announces Resignation of Guo Qifei Has as Non-Executive Director

First half 2023 earnings released: HK$0.005 loss per share (vs HK$0.014 loss in 1H 2022)

First half 2023 earnings released: HK$0.005 loss per share (vs HK$0.014 loss in 1H 2022)

Aidigong Maternal & Child Health Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023

Aidigong Maternal & Child Health Limited to Report First Half, 2023 Results on Aug 31, 2023

Executive Director recently bought HK$6.3m worth of stock

A Look At The Fair Value Of Aidigong Maternal & Child Health Limited (HKG:286)

Aidigong Maternal & Child Health Limited (HKG:286) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough

Full year 2022 earnings: EPS and revenues miss analyst expectations

Calculating The Intrinsic Value Of Aidigong Maternal & Child Health Limited (HKG:286)

Now 22% undervalued after recent price drop

Aidigong Maternal & Child Health Limited Announces Director Appointments

Is Aidigong Maternal & Child Health Limited (HKG:286) Trading At A 24% Discount?

Aidigong Maternal & Child Health Limited announced that it expects to receive HKD 224.719102 million in funding from Zhuhai Deyou Bohui Enterprise Management Consulting (Limited Partnership)

Now 24% undervalued after recent price drop

Aidigong Maternal & Child Health Limited Announces Executive Changes

Price target decreased to HK$0.60

Less than half of directors are independent

Is Aidigong Maternal & Child Health (HKG:286) Using Debt In A Risky Way?

First half 2022 earnings released: HK$0.014 loss per share (vs HK$0.006 profit in 1H 2021)

Now 25% undervalued

Estimating The Fair Value Of Aidigong Maternal & Child Health Limited (HKG:286)

First half 2022 earnings released: HK$0.014 loss per share (vs HK$0.006 profit in 1H 2021)

Aidigong Maternal & Child Health Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Aidigong Maternal & Child Health Limited Announces Resignation of Wong Kin Man as a Non-Executive Director

Aidigong Maternal & Child Health (HKG:286) Has A Somewhat Strained Balance Sheet

Aidigong Maternal & Child Health Limited, Annual General Meeting, Jun 28, 2022

Aidigong Maternal & Child Health Limited Announces Resignation of Yang Zhibo as Non-Executive Director

Price target decreased to HK$0.65

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Chairman of the Board & CEO recently bought HK$1.2m worth of stock

First half 2021 earnings released: EPS HK$0.006 (vs HK$0.007 in 1H 2020)

Independent Non Executive Director Yang Guang Mai has left the company

Aidigong Maternal & Child Health (HKG:286) Use Of Debt Could Be Considered Risky

First half 2021 earnings released: EPS HK$0.006 (vs HK$0.007 in 1H 2020)

Aidigong Maternal & Child Health Limited has completed a Follow-on Equity Offering in the amount of HKD 117.8 million.

An unknown buyer entered into an agreement to acquire 49% stake Shenzhen Wanqi Marine Bio Tech Company Limited from Aidigong Maternal & Child Health Limited (SEHK:286) for HKD 25 million.

Full year 2020 earnings released: HK$0.10 loss per share (vs HK$0.004 profit in FY 2019)

Aidigong Maternal & Child Health Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Do Institutions Own Aidigong Maternal & Child Health Limited (HKG:286) Shares?

New 90-day high: HK$0.62

Is Aidigong Maternal & Child Health Limited's (HKG:286) Stock Price Struggling As A Result Of Its Mixed Financials?

New 90-day low: HK$0.45

Aidigong Maternal & Child Health's(HKG:286) Share Price Is Down 14% Over The Past Three Years.

New 90-day low: HK$0.50

New 90-day low: HK$0.52

New 90-day low: HK$0.56